

CUMBERLAND PHARMACEUTICALS INC
Form 8-K
February 10, 2017

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of
Report
(Date of
Earliest
Event
Reported):
February
10, 2017
(February
7, 2017)

Cumberland Pharmaceuticals Inc.

(Exact name of registrant as specified in its charter)

| | | |
|--|--|---|
| Tennessee (State or other jurisdiction of incorporation) | 001-33637 (Commission File Number) | 62-1765329 (I.R.S. Employer Identification No.) |
| 2525 West End Avenue, Suite 950, Nashville, Tennessee (Address of principal executive offices) | | 37203 (Zip Code) |

Registrant's telephone number, including area code: (615) 255-0068

Not Applicable

Former name or former address, if changed since last report

Edgar Filing: CUMBERLAND PHARMACEUTICALS INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 8.01 Other Events

On February 7, 2017, Cumberland Pharmaceuticals Inc. (the "Company") issued a press release announcing the publication of a multicenter clinical study demonstrating that Caldolor® (ibuprofen) Injection delivered significant fever reduction in hospitalized children. The pivotal data published in the British BMC Pediatric Journal supported the FDA approval of Caldolor for use in this pediatric patient population. A copy of the press release is furnished as Exhibit 99.1.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cumberland Pharmaceuticals Inc.

February 10, 2017 By: Michael Bonner

Name: Michael Bonner
Title: Chief Financial Officer